Patients with chronic kidney disease, the Vytorin, cholesterol was reducing the pill, a sixth fewer heart attacks, had to unlock strokes or operations your arteries than patients, a placebo, according to the results of a study on Saturday presented.
The main advantage was in reducing the risk of heart attacks and related deaths, but reduce the artery operations and certain types of strokes, according to data specialists this weekend in Denver shows that at a meeting of the kidney.
The difference in the operations to unlock arteries - 284 in the treated group compared with 352 in the placebo group - was statistically significant, said Dr. Colin Baigent, Professor at the University of Oxford and one of the two principal investigators of the study.
But the differences between the groups was statistically insignificant for major coronary events, er.Es were 213 of such events, including heart attacks and death in the group said the cholesterol pill that took compared with 230 in the placebo group. The study, although it was great, not enough people make a significant difference in heart attacks and related deaths demonstrate had taken, he said.
Cholesterol treatment had no significant impact in slowing the progression of disease, especially in reduce the need for patients to start dialysis or a Kidney transplant, get he said.
The five-year study called the sharp study, involved more than 9,000 patients assigned to randomized, placebo or Vytorin, a Merck medicine to take.Vytorin combined in a pill two different types of treatments - a statin simvastatin and a newer drug called Ezetimibe, aka known as Zyprexa-, that lower LDL or "bad" cholesterol.
The study by researchers of at Oxford of University coordinated and funded mainly by Merck, tested, whether patients with chronic kidney disease, with high risk for heart problems are sure of greatly reduced their bad cholesterol could benefit.
The Oxford researchers avoid an upbeat press release saying shipped, the combination pill to help people with chronic kidney disease could be 25% of all heart attacks, strokes and operations to blocked arteries, open a positive but more sober assessment Merck issued its own press release.
In an interview on Saturday, Dr. Baigent said his figure was extrapolation that takes into account the number of issues may be reduced if the drug took people how required - not the way in the study had handled both in the one-third and placebo patients stop to take your pills.
"" This is an important step forward for kidney disease,"said Dr. Baigent.""We have estimated that widespread use of lipid-lowering treatment in the prevention of heart attacks, strokes and operations arteries in 250,000 people would result in blocking" with chronic kidney disease every year.
But Merck said that the risk of non-fatal heart attack, stroke, cardiac death or artery Vytorin had reduced operations by around 16 percent compared to placebo, an analysis that included a wider variety of health problems on the basis of the originally specified objective.
Based on these results, Merck said regulators to approve Vytorin for patients with chronic kidney disease in a statement Saturday, questions planned,.
0 comments:
Post a Comment